Dr. Jane L Meisel
Claim this profileWinship Cancer Institute / Emory University School of Medicine
Expert in Breast Cancer
Studies Cancer
11 reported clinical trials
24 drugs studied
Area of expertise
1Breast Cancer
Global LeaderStage IV
Stage III
ER positive
2Cancer
Stage I
Stage II
HER2 negative
Affiliated Hospitals
Clinical Trials Jane L Meisel is currently running
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
Pembrolizumab
for Triple Negative Breast Cancer
Assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating lymphocytes and serum exosomes in treatment naive triple negative breast cancer (TNBC) patients. Assess for change in tumor-infiltrating lymphocytes (TILS) both stromal (sTILS) and intraepithelial (iTILS) in newly diagnosed early stage TNBC patients treated with two doses of MK-3475 prior to lumpectomy.
Recruiting2 awards Phase 111 criteria
More about Jane L Meisel
Clinical Trial Related1 year of experience running clinical trials · Led 11 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Jane L Meisel has experience with
- Pembrolizumab
- Tucatinib
- Trastuzumab
- Pertuzumab
- Fulvestrant
- Trastuzumab Deruxtecan
Breakdown of trials Jane L Meisel has run
Breast Cancer
Cancer
Peripheral Neuropathy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jane L Meisel specialize in?
Jane L Meisel focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jane L Meisel currently recruiting for clinical trials?
Yes, Jane L Meisel is currently recruiting for 5 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Jane L Meisel has studied deeply?
Yes, Jane L Meisel has studied treatments such as Pembrolizumab, Tucatinib, Trastuzumab.
What is the best way to schedule an appointment with Jane L Meisel?
Apply for one of the trials that Jane L Meisel is conducting.
What is the office address of Jane L Meisel?
The office of Jane L Meisel is located at: Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia 30322 United States. This is the address for their practice at the Winship Cancer Institute / Emory University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.